Northland Capital Markets Initiates Coverage On TriSalus Life Sciences with Outperform Rating, Announces Price Target of $12.5
Portfolio Pulse from Benzinga Newsdesk
Northland Capital Markets has initiated coverage on TriSalus Life Sciences with an Outperform rating and set a price target of $12.5.
October 25, 2024 | 4:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Northland Capital Markets has initiated coverage on TriSalus Life Sciences with an Outperform rating and a price target of $12.5, indicating a positive outlook.
The initiation of coverage with an Outperform rating and a specific price target of $12.5 by Northland Capital Markets suggests a positive sentiment towards TriSalus Life Sciences. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100